DexCom Inc (DXCM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $30.44B
Last updated: Nov 17, 2026 at 4:39 PM ET
DexCom Inc (DXCM) Stock Chart
DexCom (DXCM) has a latest price of $82.04 on Nov 17, 2026, 11.4% below its 52-week high of $92.59. Its price rose 41.3% over the past 12 months. The month-end price rose 320.7% over the 10 years through Oct 2026, a compound annual rate of 15.5%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $155.80 in Oct 2021 and its lowest $11.24 in Oct 2017, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart DXCM with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for DXCM.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 8.7%, and over 6 months it rose 22.5%. The month-end price fell 7.4% over the 3 years through Oct 2026, a compound annual decline of 2.5%.
| Period | Change |
|---|---|
| 1 month | -4.6% |
| 3 months | -8.7% |
| 6 months | +22.5% |
| 12 months | +41.3% |
| 12 months, with dividends | +41.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -7.4% | -2.5% |
| 5 years | -47.2% | -12.0% |
| 10 years | +320.7% | +15.5% |
Price by Year
Its best calendar year was 2018, when the price rose 108.7%, and its weakest was 2024, when it fell 37.3%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $82.29 | +24.0% |
| 2025 | $66.37 | -14.7% |
| 2024 | $77.77 | -37.3% |
| 2023 | $124.09 | +9.6% |
| 2022 | $113.24 | -15.6% |
| 2021 | $134.24 | +45.2% |
| 2020 | $92.43 | +69.0% |
| 2019 | $54.69 | +82.6% |
| 2018 | $29.95 | +108.7% |
| 2017 | $14.35 | -3.9% |
Trading Range
The price is 2.5% below its 50-day average of $84.12 and 9.1% above its 200-day average of $75.17.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $82.04 | |
| 52-week high | $92.59 | -11.4% |
| 52-week low | $56.72 | +44.6% |
| 50-day average | $84.12 | -2.5% |
| 200-day average | $75.17 | +9.1% |
Price Risk
Over 3 years, its largest fall from a peak was 61.0%.
| Measure | Value |
|---|---|
| 1-year beta | 0.74 |
| Largest fall, 1 year | -22.6% |
| Largest fall, 3 years | -61.0% |
Valuation
DexCom traded at 31.8x earnings at the end of 2025, against a 5-year median of 67.5x.
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About DXCM
What is DXCM's 1-year price change?
DexCom's price rose 41.3% over the past 12 months. With dividends included, the 12-month total return was 41.3%.
What is DXCM's 5-year price change?
DexCom's month-end price fell 47.2% over the 5 years through Oct 2026, a compound annual decline of 12.0%. These figures leave out dividends.
What is DXCM's 52-week high and low?
DexCom's 52-week high is $92.59 and its 52-week low is $56.72. Its latest price of $82.04 on Nov 17, 2026 is 11.4% below the high.
What is DXCM's beta?
DexCom's 1-year beta against the S&P 500 is 0.74, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 22.6%.
Is the DXCM chart free?
Yes. Advanced Charting for DXCM is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
DXCM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors